Acadian Asset Management Portfolio holdings
AUM
$48.4B
1-Year Return
32.04%
This Quarter Return
+8.62%
1 Year Return
+32.04%
3 Year Return
+133.69%
5 Year Return
+272.69%
10 Year Return
+761.99%
AUM
$32.2B
AUM Growth
-$282M
(-0.87%)
Cap. Flow
-$1.8B
Cap. Flow
% of AUM
-5.59%
Top 10 Holdings %
Top 10 Hldgs %
23.59%
Holding
2,410
New
656
Increased
561
Reduced
741
Closed
336
Top Buys
| 1 |
Ericsson
ERIC
|
+$303M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$264M |
| 3 |
Citigroup
C
|
+$196M |
| 4 |
Fortinet
FTNT
|
+$162M |
| 5 |
Infosys
INFY
|
+$144M |
Top Sells
| 1 |
Pinduoduo
PDD
|
+$419M |
| 2 |
NVIDIA
NVDA
|
+$417M |
| 3 |
Amazon
AMZN
|
+$388M |
| 4 |
Meta Platforms (Facebook)
META
|
+$288M |
| 5 |
CRH
CRH
|
+$272M |
Sector Composition
| 1 | Technology | 34.81% |
| 2 | Financials | 16.08% |
| 3 | Communication Services | 9.48% |
| 4 | Consumer Discretionary | 9.1% |
| 5 | Healthcare | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
1801
Avadel Pharmaceuticals
AVDL
$1.54B
| $47K | ﹤0.01% |
+3,639
| New | +$47K |
|
1802
Corteva
CTVA
$48.7B
| $47K | ﹤0.01% |
812
-18,867
| -96% | -$1.09M |
|
1803
Immunome
IMNM
$783M
| $47K | ﹤0.01% |
+3,237
| New | +$47K |
|
1804
John Wiley & Sons Class A
WLY
$2.21B
| $47K | ﹤0.01% |
985
-33,918
| -97% | -$1.62M |
|
1805
Acumen Pharmaceuticals
ABOS
$81.8M
| $46K | ﹤0.01% |
+18,643
| New | +$46K |
|
1806
C3.ai
AI
$2.15B
| $46K | ﹤0.01% |
+1,924
| New | +$46K |
|
1807
Cars.com
CARS
$815M
| $46K | ﹤0.01% |
+2,781
| New | +$46K |
|
1808
CG Oncology
CGON
$2.56B
| $46K | ﹤0.01% |
+1,227
| New | +$46K |
|
1809
Digital Realty Trust
DLR
$59.3B
| $46K | ﹤0.01% |
285
-25,376
| -99% | -$4.1M |
|
1810
Enliven Therapeutics
ELVN
$1.14B
| $46K | ﹤0.01% |
+1,825
| New | +$46K |
|
1811
Grindr
GRND
$2.96B
| $46K | ﹤0.01% |
+3,856
| New | +$46K |
|
1812
Hims & Hers Health
HIMS
$10.8B
| $46K | ﹤0.01% |
+2,516
| New | +$46K |
|
1813
ImmunityBio
IBRX
$2.43B
| $46K | ﹤0.01% |
+12,432
| New | +$46K |
|
1814
Mersana Therapeutics
MRSN
$36.7M
| $46K | ﹤0.01% |
976
-1,884
| -66% | -$88.8K |
|
1815
Minerva Neurosciences
NERV
$15M
| $46K | ﹤0.01% |
17,416
-7
| -0% | -$18 |
|
1816
Pitney Bowes
PBI
$1.96B
| $46K | ﹤0.01% |
+6,595
| New | +$46K |
|
1817
Virgin Galactic
SPCE
$180M
| $46K | ﹤0.01% |
+7,637
| New | +$46K |
|
1818
Triumph Financial, Inc.
TFIN
$1.42B
| $46K | ﹤0.01% |
+584
| New | +$46K |
|
|
TRIB
1819
Trinity Biotech
TRIB
$4.32M
| $46K | ﹤0.01% |
41,839
-30,271
| -42% | -$33.3K |
|
1820
Wintrust Financial
WTFC
$9.17B
| $46K | ﹤0.01% |
433
| – | – |
|
1821
AN2 Therapeutics
ANTX
$33.6M
| $45K | ﹤0.01% |
42,335
-44,613
| -51% | -$47.4K |
|
1822
BILL Holdings
BILL
$5.38B
| $45K | ﹤0.01% |
864
-41,075
| -98% | -$2.14M |
|
1823
Novavax
NVAX
$1.29B
| $45K | ﹤0.01% |
+3,602
| New | +$45K |
|
1824
StoneX
SNEX
$5.02B
| $45K | ﹤0.01% |
+831
| New | +$45K |
|
1825
Teradata
TDC
$1.99B
| $45K | ﹤0.01% |
1,499
-10,616
| -88% | -$319K |
|